Bioventus
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 weeks.
- Its last 4 Sell calls were actually followed by a +31% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +10.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 4.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation B
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 12.2x | Better than 70% |
| Forward P/E | 20.8x | Better than 34% |
| Price / Sales | 1.2x | Better than 72% |
| P/E vs own 5-yr range | 65th pctl | Better than 44% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 3.5% | Better than 41% |
| Free cash flow CAGR (3Y) | 162.0% | Better than 97% |
Profitability B
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 68.3% | Better than 82% |
| Operating margin | 9.9% | Better than 51% |
| Net margin | 4.0% | Better than 40% |
| Return on equity | 13.7% | Better than 64% |
| Return on invested capital | 8.8% | Better than 64% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -31.3% | Better than 17% |
| 6-month return | 6.5% | Better than 67% |
| 12-month return (ex latest month) | 107.7% | Better than 96% |
| Distance below 52-week high | 37.8% | Better than 31% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.7x | Better than 48% |
| Debt to assets | 43.0% | Better than 23% |
| Interest coverage | 2.0x | Better than 36% |
| Free cash flow / net income | 317.2% | Better than 87% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 68.7% | Better than 76% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 9.95
- Open
- 9.85
- Day range
- 9.81 - 10.17
- Avg price
- 9.90
- Volume
- 612.44K
- Turnover
- 6.06M
- Turnover ratei
- 1.83%
- Volume ratioi
- 1.07
- Amplitudei
- 3.62%
- 52-week rangei
- 7.02 - 15.89
Valuation
- P/Ei
- 29.94
- P/E (TTM)i
- 12.20
- P/Bi
- 2.81
- EPSi
- 0.33
- Book value / shi
- 3.51
- Net profit
- 22.60M
- Net assets
- 240.48M
Share structure
- Market cap
- 676.53M
- Float capi
- 330.71M
- Shares out
- 68.47M
- Float sharesi
- 33.47M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2021-02-11
37.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-2.19M net over the window
Short interest
- Shares short
- 3.02M
- % of floati
- 4.43%
- Days to coveri
- 6.62
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Bioventus (BVS)?
Bioventus last traded at 9.88. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Bioventus's market cap?
About 676.53M.
What is the P/E ratio of Bioventus?
The trailing twelve-month P/E is 12.20, below its own 5-year average of 32.69 — in the middle of its historical range (64.96% percentile). See the Valuation tab for the full history.
Does Bioventus pay a dividend?
Bioventus does not currently pay a regular dividend.
Is Bioventus a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 16.67, which implies 68.7% upside from the current price. This is not investment advice.
What is Bioventus's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Bioventus a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Bioventus discussion 0 comments